The impact of prostate artery embolization (PAE) on the the physical history and pathophysiology of benign prostatic hyperplasia (BPH)

Konstantinos Stamatiou

Urology Department, Tzanio Hospital, Piraeus, Greece.

Summary

Aim: Prostate artery embolization (PAE) is a non-invasive modality for the treatment of benign prostate hypertrophy (BPH) related lower urinary tract symptoms (LUTS). As a relatively new procedure, data determining the clinical success is somehow scarce. In the present article we examine the current clinical outcome measures in order to identify the most accurate.

Results: Current imaging outcome measures are consistent with clinical ones only in the group of patients with adenomatous-dominant BPH while are inconsistent in patients with small sized adenomas.

Conclusions: Additional studies and/or evaluation tools are needed in order to provide accurate evaluation of clinical success in the subgroup of patients with non-adenomatous-dominant BPH while they may inspire new options and novel techniques for both BPH treatment and treatment-follow up.

Key words: Benign prostatic hyperplasia; Lower urinary tract symptoms; Prostate artery embolization.

Submitted 12 September; Accepted 9 December 2018

INTRODUCTION

BPH is a histologic diagnosis characterized by proliferation of the cellular elements of the prostate. This involves both stromal and epithelial cells, resulting in the formation of large, fairly discrete nodules in the transition zone of the prostate (1). Almost 50% of BPH patients with enlarged prostate have LUTS (2).

The last are the result of either mechanical obstruction due to glandular enlargement, or dynamic obstruction secondary to contraction of the smooth muscles of the prostate, urethra and bladder neck (3). Mild symptoms usually do not require treatment however moderate and severe symptoms could be treated with either medical therapy or surgery.

Currently prostatic arterial embolization (PAE) was emerged as a feasible procedure to treat lower urinary tract symptoms associated with BPH. PAE is the less invasive non-pharmacological treatment. It is performed under local anaesthesia, usually by a right groin approach through the right femoral artery. It consists of selective embolization of prostatic arteries with small-diameter hydrophilic microcatheters and polyvinyl alcohol (PVA) in order to cause interruption of arterial flow. Initial studies showed that PAE led to reduction of the prostatic volume, symptom remission and improvements in quality of life. However, as a relatively new procedure, data determining the accurate evaluation of clinical success of PAE is somehow scarce. In the present article we aim to investigate the potential role of elastography on the evaluation of clinical success of PAE on the treatment of benign prostatic hyperplasia (BPH).

MATERIALS AND METHODS

A search was performed in MEDLINE, NCBI, Pubmed, Cochrane Library and other electronic libraries using the terms “prostate artery embolization AND benign prostatic hyperplasia”. The articles selected were checked for the relevancy of their content to the discussed subject. The bibliographic information in the selected articles was checked for relevant publications that had not been included in the original search.

RESULTS

Since 2008 when embolization of prostatic arteries for the treatment of LUTS associated with BPH has been held for the first time, a total of 104 articles on PAE were published. After being checked for the relevancy of their content to the discussed subject, 22 papers were discarded after lecture of summary and 61 after lecture of the full paper. Finally, 21 peer-reviewed studies providing data on one or more clinical outcomes were retrieved. A recent meta-analysis of 6 large studies showed improvement in $Q_{\text{max}}$, PVR, IPSS, and QoL endpoints at 12 months, with a low incidence of serious adverse effects (0.3%). Another recent meta-analysis of three studies comparing PAE with other treatments found greater maximum urine flow restoration and reduction in prostate volume in PAE group in relation to controls (4). Current experience shows also promising results in symptom remission and improvements in quality of life. However the overall number of PAE patients and studies meeting reliability criteria is small. Moreover, no generally accepted definition for clinical success exists (Table 1). In fact, principal outcome assessment varies among studies and could be either objective or subjective, laboratory, clinical or both. For example, regaining the ability to urinate after PAE is a measurable size whereas questionnaire-based self-reported improvement of both urination and QoL are not. Furthermore, as long as the exact mechanism by which...
Table 1. Variability of Main outcome criteria among studies.

<table>
<thead>
<tr>
<th>Authors</th>
<th>N. patients</th>
<th>Main outcome criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li P et al, 2017 (18)</td>
<td>24</td>
<td>IPSS, PVR, QoL, PSA</td>
</tr>
<tr>
<td>Hwang JH et al, 2017 (19)</td>
<td>9</td>
<td>IPSS, PV, QoL, Qmax</td>
</tr>
<tr>
<td>Little MV et al, 2017 (13)</td>
<td>12</td>
<td>MP-MRI, IPSS, EQ-5D-SS</td>
</tr>
<tr>
<td>Rampoldt A et al, 2017 (20)</td>
<td>43</td>
<td>discontinuation of BIC, IPSS, PV, QoL, Clavien II</td>
</tr>
<tr>
<td>Bilhom T et al, 2016 (21)</td>
<td>183</td>
<td>24-hour post-PAE PSA, MRI</td>
</tr>
<tr>
<td>Isaacson AJ et al, 2016 (22)</td>
<td>12</td>
<td>IPSS-QoL</td>
</tr>
<tr>
<td>Picco et al, 2016 (23)</td>
<td>152</td>
<td>IPSS, QoL, need for additional treatment</td>
</tr>
<tr>
<td>Wang MQ et al, 2016 (14)</td>
<td>157</td>
<td>IPSS, QoL, Qmax, PV, PVR, and PSA</td>
</tr>
<tr>
<td>Amoury G et al, 2016 (24)</td>
<td>32</td>
<td>Mean IPSS, mean QoL, mean Qmax, mean PV</td>
</tr>
<tr>
<td>de Assis AM et al, 2015 (10)</td>
<td>35</td>
<td>MRI, uroflowmetry, IPSS</td>
</tr>
<tr>
<td>Bagla S et al, 2015 (11)</td>
<td>78</td>
<td>AUA symptom index, QoL, or IIEF</td>
</tr>
<tr>
<td>Russo GI et al, 2015 (25)</td>
<td>287</td>
<td>IPSS, IIEF-5, PF, PV, PVR, IPSS-QoL</td>
</tr>
</tbody>
</table>


PAE affects BPH induced LUTS remains unclear, reduction in prostate volume and serum PSA value may not be the most adequate outcome measures. In fact, clinical success – in terms of IPSS and Qmax – is not always analogous to prostate volume reduction. Moreover, the reduction on prostate volume occurs progressively and stabilized within six months of the procedure. Yet, up to 20% of patients undergoing PAE show no prostate volume reduction 3 months after the procedure (5).

A small MRI study showed that reduction of the prostate volume after embolization was significant only in patients with infarcts (6). In this study infarcts were seen in only 70.6% of the subjects, exclusively in the central gland. However, a retrospective study showed that prostate volume decrease occurs in both central and peripheral zones (7), a fact suggesting disproportion between infarcts and reduction of the prostate volume. A small MRI study proposed infarcts to be a good predictor of clinical success after PAE in patients with AUR secondary to BPH (8), it seems that it is not the case.

A significantly high PSA elevation occurs in the 24 hours after PAE. During follow-up, mean PSA decreases to a level significantly lower than at baseline. This is suspected to result from prostate inflammation and ischemia due to embolization and suggests prostate cellular apoptosis after PAE (9). However, no statistically significant correlation was detected between PSA level 24 hours after PAE and prostate volume reduction at 3 months of follow-up (10). In contrast, a statistically significant negative correlation between PSA level elevation 24 hours after PAE and IPSS decrease at 3 months of follow-up was reported (31). It should be mentioned that other conditions that can increase PSA levels such as pre-existing inflammation, pre-treatment prostate manipulations (e.g. catheterization) and prostate size may bias this association. Moreover IPSS has inadequate sensitivity and specificity to be used as a stand-alone tool in the evaluation of clinical success of a new method such as PAE. Although, a study proposed PSA elevation after PAE to be a prognostic factor for predicting patient response to PAE (31), more research is needed in order to confirm this suggestion.

In fact, uncertainty regarding the role of pre-treatment prostate volume in the successfulness of PAE exists. Bagla et al performed an analysis on 78 consecutive patients undergoing PAE, comparing prostate volume groups (group 1 < 50 cm³, group 2: 50-80 cm³, group 3 > 80 cm³) at baseline and follow-up to assess for differences in outcomes of American Urological Association (AUA) symptom index, quality of life (QOL)-related symptoms, and International Index of Erectile Function (IIEF). According to their result no statistically significant differences in the above parameters was found between groups (11). Other authors suggest that patients with a smaller prostate (i.e., volume < 30 cm³) should excluded because PAE is believed to work based on prostate volume reduction, which will be more limited in patients with almost normal sized prostates (12).

In accordance to the above, Little et al., found a statistically significant reduction in prostate volume following embolization with a median reduction of 34% (30-55) in the group of patients with adenomatous-dominant BPH (AdBPH), compared to a mean volume reduction of 22% in the non-AdBPH group. IPSS and QoL score significantly improved in the AdBPH group while there was no deterioration in sexual function in either group post-PAE (13). Similarly, Wang et al., found the clinical and imaging outcomes of PAE to be better in patients with larger prostate glands than medium-sized ones (14).

**Discussion**

The abovementioned findings may indicate a greater impact of PAE induced ischaemia in the adenomatous stromal element of the prostate gland. However, clinical effect occurs progressively and stabilized within six months, therefore it is possible that PAE resolves dynamic obstruction also but at a slower rate. The exact mechanism by which PAE resolves dynamic obstruction is the shrinkage of the enlarged prostate gland as a result of PAE induced ischemic infarction. In contrast, the exact mechanism(s) by which PAE resolves dynamic obstruction...
obstruction remains practically unknown (15). Currently used imaging techniques are not providing relative information while knowledge on the histology of prostate tissue following PAE is extremely limited. Camara-Lopes et al., described early prostate tissue histology changes after PAE. Along with embolic material (bright eosin-red spheroids filling the vessel lumens) they observed also areas of ischemic necrosis. The transition zone between necrotic and normal prostate tissue was characterized by inflammatory reactions containing ribs of neutrophils, lymphocytes and proliferated fibroblasts. Nodular fibrosis with hyalination as a consequence of the healing process was present in some areas associated with squamous metaplasia of the epithelium lining the surrounding glands (9).

Yet there are no studies examining long term prostate tissue histology changes after PAE. However, given that PSA values decrease to a level significantly lower than at baseline but no ejaculation disorders occur it could be assumed that prostate gland return in fully functional state after PAE. As a matter of fact, metaplasia that occurs in response to necrosis and inflammation may represent an adaptive substitution of cells that are sensitive to stress by cell types better able to withstand the adverse environment and is reversible.

On the other hand, the regained ability to urinate after PAE may be associated with changes in stromal elements. Because fibroblasts are typically activated following injury and are the main producers of extracellular matrix proteins, their role as reparative cells is widely recognized (16). Fibroblasts may play a critical role in remodeling of the prostate following PAE and thus, clinical success might be also related to the regained elasticity.

The stiffness of a tissue, or its ability to resist deformation when subjected to an applied force, is indicative of the regenerative state in most organs in the body. Tissue stiffness is largely defined by chemistry and associated micro-macro structure of the extracellular matrix (ECM). Therefore, the ability to estimate ECM stiffness may assist in monitoring healing after PAE and allow estimation of clinical success.

Currently, elastic properties, of biomaterials including stiffness or shear modulus, can be investigated by elastography. The last is the only specialized imaging-based method available to spatially map strain fields, it is cost-effective and safe (17). Studies comparing elastographic findings with the conventional outcome measures are needed in order to investigate the role for the elastography on the evaluation of the efficacy of PAE on the treatment of BPH.

CONCLUSION

PAE is a safe and efficient method for the treatment of both mechanical and dynamic component of bladder outlet obstruction in patients with BPH. Current imaging outcome measures are consistent with clinical ones in the group of patients with adenomatous-dominant BPH while are inconsistent in patients with small sized adenomas. Elastography may be useful for the evaluation of PAE outcome in these patients while may shed light on the pathophysiology of BPH and inspire new options and novel techniques for both treatment and follow up.

REFERENCES


Correspondence
Stamatiou Konstantinos, MD (Corresponding Author)
stamatiouk@gmail.com
Urology Department, Tzaneio Hospital,
2 Salepoula str. 18536 Piraeus, Greece